Winterlight

About Winterlight

Winterlight Labs offers a sophisticated platform for detecting and monitoring cognitive and mental health conditions through speech analysis. The company was spun out of the University of Toronto in 2015, founded by Liam Kaufman, Katie Fraser, and Frank Rudzicz, stemming from extensive research conducted within the university's Computational Linguistics department. Co-founder Frank Rudzicz, a scientist and professor with expertise in computer science, machine learning, and natural language processing, focused his research on analyzing speech for patterns associated with diseases. This academic foundation was driven by personal experiences, including witnessing his grandparents' cognitive decline, which motivated him to apply his childhood interest in artificial intelligence to healthcare challenges. Co-founder and CEO Liam Kaufman brought a unique background, having studied psychology and neurosciences before transitioning to computer science, driven by a frustration with the software available to neuroscientists. His previous entrepreneurial experience includes founding Understoodit, a classroom feedback tool acquired in 2013.

The core of Winterlight's business is a tablet-based assessment that analyzes short, one-to-five-minute samples of a person's speech. By evaluating over 550 linguistic and acoustic features—such as pauses, pacing, and vocabulary—the company's AI-driven technology creates objective digital biomarkers of cognitive health. This service is primarily aimed at pharmaceutical companies and life sciences firms conducting clinical trials for conditions like Alzheimer's disease, dementia, schizophrenia, and depression. These clients use the technology to screen patients, measure disease progression, and assess the effectiveness of new treatments more efficiently than traditional methods. Revenue is generated by providing this technology and its analytical services to these partners, with five of the top ten global life sciences companies counted among its customers.

Winterlight's platform offers a significant advantage over conventional cognitive tests, which are often subjective, time-consuming, and must be administered in a clinical setting. The company's assessment can be conducted remotely, reducing the burden on patients and enabling more frequent data collection. This automated and objective scoring system has demonstrated high accuracy in peer-reviewed studies. In January 2023, Winterlight Labs was acquired by Cambridge Cognition for £7 million, a move designed to combine Winterlight's free-speech analysis capabilities with Cambridge Cognition's portfolio of digital brain health solutions, creating a leader in vocal biomarker technology.